Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
Abstract Background The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. Methods We retrospectively analyzed data from breast cancer patients who bega...
Main Authors: | Fan Yang, Xiang Huang, Chunxiao Sun, Jianbin Li, Biyun Wang, Min Yan, Feng Jin, Haibo Wang, Jin Zhang, Peifen Fu, Tianyu Zeng, Jian Wang, Wei Li, Yongfei Li, Mengzhu Yang, Jun Li, Hao Wu, Ziyi Fu, Yongmei Yin, Zefei Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-6639-4 |
Similar Items
-
Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
by: Ye Yuan, et al.
Published: (2022-12-01) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01) -
Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer
by: Michela Donadio
Published: (2018-06-01) -
Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01) -
Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)